Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05225948
Other study ID # ESCAPE-SVD
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 30, 2021
Est. completion date October 31, 2025

Study information

Verified date February 2024
Source The First Hospital of Jilin University
Contact Yi Yang, MD, PhD
Phone 0086-13756661217
Email doctor_yangyi@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine effects of remote ischemic conditioning on dynamic cerebral autoregulation, blood pressure and heart rate variability in patients with cerebral small vessel disease.


Description:

In this study, 100 cases of cerebral small vessel disease in the First Hospital of Jilin University are divided into 2 groups according to the intention of the individual. On the basis of standard medical treatment, the experimental group receive in-hospital remote ischemic conditioning treatment for 200 mmHg, 2 times per day; the control group receive remote ischemic conditioning for 60 mmHg, 2 times per day during the period of hospitalization. Patients in both groups undergo several dynamic cerebral autoregulation and beat-to-beat monitoring respectively at baseline, 3-4 days of remote ischemic conditioning and the time the last in-hospital remote ischemic conditioning performed. Two groups will be followed up for 90 days to evaluate the effects of remote ischemic conditioning therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date October 31, 2025
Est. primary completion date July 1, 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - 1) Regardless of age, sex; - 2) Patients are diagnosed with cerebral small vessel disease, and neuroimaging shows new subcortical lacunar infarction (in line with one of the following): ? MRI examination Diffusion-weighted imaging (DWI) phase shows high signal intensity [Apparent Diffusion Coefficient (ADC) diffusion restriction] lesions < 20 mm diameter in subcortical, basal ganglia or brainstem , with or without corresponding clinical symptoms; ? With new clinical symptoms, MRI examination FLAIR sequence shows corresponding FLAIR high signal intensity lesions [diameter < 20 mm]) in subcortical, basal ganglia or pons; - 3) Remote ischemic conditioning can be started within 7 days from onset; - 4) Willing to participate and sign the informed consent. Exclusion Criteria: - 1) Vascular stenosis > 50% by Transcranial Doppler (TCD); - 2) Previous history of intracranial hemorrhage or major bleeding in other parts of the body; - 3) Previous history of atrial fibrillation or myocardial infarction within 6 months; - 4) Moyamoya disease or hereditary cerebral small vessel disease, such as mitochondrial encephalopathy, CADASIL or Fabry; - 5) The patients who had clear non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy; - 6) Severe hepatic and renal diseases, cancer or other major diseases related to medical and surgical procedures; - 7) The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb; Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; - 8) Significant coagulation abnormalities; - 9) Pregnant or lactating women; - 10) The patients with disturbance of consciousness or agitation who cannot cooperate to dynamic cerebral autoregulation monitoring or beat-to-beat blood pressure monitoring; - 11) Previous remote ischemic conditioning therapy or similar treatment; - 12) Unwilling to be followed up or treated for poor compliance; - 13) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission; - 14) Other conditions that the researchers think are not suitable for the group.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Remote ischemic conditioning
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization.
Sham remote ischemic conditioning
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization.

Locations

Country Name City State
China The First Hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Yi Yang

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase Difference(PD) in Degree PD is a dynamic cerebral auto-regulation parameter derived from transfer function analysis. within 7 days of RIC
Primary Differences of blood pressure variability (BPV) in Degree after in-hospital remote ischemic conditioning finished between two groups BPV is defined as blood pressure oscillations in relation to the mean values. within 7 days of RIC
Primary Differences of heart rate variability (HRV) in Degree after in-hospital remote ischemic conditioning finished between two groups HRV is defined as heart rate oscillations in relation to the mean values. within 7 days of RIC
Secondary Differences of BPV in Degree after 3-4 days remote ischemic conditioning treatment between two groups BPV is defined as blood pressure oscillations in relation to the mean values. 3-4 days after RIC
Secondary Differences of HRV in Degree after 3-4 days remote ischemic conditioning treatment between two groups HRV is defined as heart rate oscillations in relation to the mean values. 3-4 days after RIC
Secondary PD in Degree PD is a dynamic cerebral auto-regulation parameter derived from transfer function analysis. 3-4 days after RIC
Secondary Differences in modified Rankin Scale (mRS) Score between two groups Modified Rankin Scale (mRS) Score ranged from 0 to 6, a low value represents a better outcome. 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04041349 - Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease Phase 4
Recruiting NCT04109963 - Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment Phase 2
Not yet recruiting NCT06416371 - Retinal Vessel Leakage in Cerebral Small Vessel Disease
Not yet recruiting NCT05967728 - Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care Phase 2
Completed NCT05714813 - Circuit Training and Retina N/A
Not yet recruiting NCT06077305 - A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke
Not yet recruiting NCT06061692 - Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study(TOPS-CSVD) Phase 4
Recruiting NCT04962295 - China Imaging-based Biobank of Cerebral Small Vessal Diseases
Completed NCT02801032 - Effect of Tadalafil on Cerebral Large Arteries in Stroke Phase 2
Not yet recruiting NCT05594966 - Neuroimaging Combining Biomarkers for Identifying Long-term Cognitive Dysfunction and Delirium
Terminated NCT02890888 - Effect of Hyperbaric Oxygen on Functional Connectivity in Patients With Cerebral Small Vessel Disease N/A
Recruiting NCT04318119 - Cerebral Small Vessel Disease Registry Study
Recruiting NCT03906123 - The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia N/A
Recruiting NCT05306834 - Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease N/A
Not yet recruiting NCT05583266 - Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM) Phase 4
Recruiting NCT05173896 - Improving Cerebral Blood Flow and Cognition in Patients With Cerebral Small Vessel Disease. The ETLAS-2 Trial Phase 2
Recruiting NCT01819441 - Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Phase 4
Recruiting NCT01688505 - Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function N/A
Recruiting NCT04330222 - Cambridge 7 Tesla Cerebral Small Vessel Disease Study
Recruiting NCT04298866 - White Matter Hyperintensities Subtypes in Cerebral Small Vessel Disease : 7 Tesla Ultra-high Resolution Imaging MRI N/A